Financials in USD. Standardized financial statements.
A compact view of how Antisense Therapeutics Limited turns revenue into operating income and net income.
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $2.97M | $1.58M | $1.78M | $577,764 | $668,433 | $586,788 | $272,424 | $69,115 | $1.00M | $3.86M |
| Revenue Growth? | +87.9% | -11.1% | +207.7% | -13.6% | +13.9% | +115.4% | +294.2% | -93.1% | -74.1% | 0.0% |
| Cost of Revenue? | $62,146 | $95,199 | $89,218 | $103,319 | $107,601 | $5,377 | $6,413 | $207,814 | $317,383 | $205,353 |
| Gross Profit? | $2.91M | $1.48M | $1.69M | $474,445 | $560,832 | $581,411 | $266,011 | -$138,699 | $682,617 | $3.66M |
| Gross Margin? | +97.9% | +94.0% | +95.0% | +82.1% | +83.9% | +99.1% | +97.6% | -200.7% | +68.3% | +94.7% |
| Operating Expenses? | $14.74M | $13.34M | $7.61M | $8.68M | $6.67M | $3.58M | $2.61M | $3.29M | $4.07M | $3.89M |
| Operating Income? | -$11.83M | -$13.34M | -$7.61M | -$8.68M | -$6.67M | -$3.58M | -$2.62M | -$3.22M | -$3.07M | -$24,923 |
| EBITDA? | -$11.90M | -$11.37M | -$5.83M | -$8.10M | -$5.99M | -$3.58M | -$2.61M | -$3.21M | -$3.07M | -$16,751 |
| Income Before Tax | -$11.92M | -$11.38M | -$5.81M | -$8.06M | -$5.91M | -$3.52M | -$2.60M | -$2.75M | -$2.51M | $706,918 |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | -$576,690 | -$272,424 | $0 | $0 | $0 |
| Net Income? | -$11.92M | -$11.38M | -$5.81M | -$8.06M | -$5.91M | -$2.94M | -$2.33M | -$2.75M | -$2.51M | $706,918 |
| EPS? | $-0.01 | $-0.02 | $-0.01 | $-0.01 | $-0.01 | $-0.01 | $-0.01 | $-0.02 | $-0.01 | $0.00 |
| Diluted EPS? | $-0.01 | $-0.02 | $-0.01 | $-0.01 | $-0.01 | $-0.01 | $-0.01 | $-0.02 | $-0.01 | $0.00 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality